FLUIFORT ® - Carbocysteine

FLUIFORT ® is a drug based on Carbocysteine lysine salt

THERAPEUTIC GROUP: Mucolytics

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications FLUIFORT ® - Carbocisteina

FLUIFORT ® is used as a mucolytic in the treatment of respiratory tract diseases characterized by hypersecretion of thick and viscous mucus.

FLUIFORT ® action mechanism - Carbocysteine

FLUIFORT ® is a medicinal specialty based on Carbocysteine, an active ingredient with multiple biological activities that materialize in the fluidifying and mucolytic action.

More precisely, several studies have shown how this active ingredient can:

Restore the synthesis of glycoproteins, rebalancing the cell's biosynthetic capabilities;
Reduce the synthesis of sialoproteins whose presence is crucial in maintaining the rheological properties of the mucus;
Increase chlorine secretion, attracting water and making the mucus more fluid;
Protect the cell from oxidative damage induced by reactive oxygen species;
Induce the synthesis of IgA and other mediators able to increase the barrier function of the respiratory mucosa.

Following good intestinal absorption, Carbocysteine is rapidly concentrated at the lung level and subsequently eliminated mainly through the urine.

Studies carried out and clinical efficacy

USE OF CARBOCISTEIN IN THE PEDIATRIC POPULATION

PLoS One. 2011; 6 (7): e22792.

Very interesting European study that evaluates the potential adverse reactions of Carbocysteine for systemic use in the pediatric population, demonstrating the greatest risk of vomiting, breathing difficulties and bronchospasm. These data suggest greater caution in the use of this active ingredient especially in the pediatric population.

THE ANTIOXIDANT ACTION OF CARBOCISTEIN

Eur Cytokine Netw. 2003 Jan-Mar; 14 (1): 20-6.

Work that demonstrates how among the therapeutic properties of Carbocysteine can be counted the antioxidant, important in helping the mucolytic therapeutic effect, reducing the inflammatory stimulus exerted by oxygen free radicals and different cytokines.

CARBOCISTEIN IN CYSTIC FIBROSIS

J Int Med Res. 1995 Jul-Aug; 23 (4): 284-93.

Interesting study that demonstrates how Carbocysteine can be effective in improving the respiratory capacity of patients with cystic fibrosis, also optimizing the results of the various functional tests.

Method of use and dosage

FLUIFORT ®

Granulated for 2.7 g oral solution of Carbocysteine lysine salt per sachet:

9% syrup of Carbocysteine lysine salt.

The therapy, both in terms of doses and duration, must necessarily be defined by your doctor based on the physical characteristics of the patient, his general health and the seriousness of the clinical conditions.

Generally taking a sachet a day for a few days is sufficient to guarantee an improvement in the complained symptomatology.

Warnings FLUIFORT ® - Carbocysteine

The use of FLUIFORT ® must necessarily be preceded by a careful medical examination in order to assess the prescriptive appropriateness and the possible presence of conditions incompatible with the therapy based on Carbocysteine.

Particular caution should also be reserved for patients suffering from renal pathologies, whose excretion capacity of the drug could obviously be compromised.

In order to avoid possible mucus stagnation, it would be advisable to check the patient's expectorant capacity before administering FLUIFORT ®.

FLUIFORT ® contains aspartame, therefore its intake is contraindicated in patients with phenylketonuria.

PREGNANCY AND BREASTFEEDING

The absence of studies able to accurately delineate the safety profile of Carbocysteine for fetal health, extend the aforementioned contraindications to the use of FLUIFORT ® also to pregnancy and the subsequent period of breastfeeding.

Interactions

At the moment active ingredients capable of altering the pharmacokinetic and pharmacodynamic characteristics of carbocysteine to such an extent as to induce the appearance of clinically relevant manifestations are not known.

Contraindications FLUIFORT ® - Carbocysteine

The use of FLUIFORT ® is contraindicated in children under the age of 12, in patients who are hypersensitive to the active substance or to one of its excipients and in patients with gastro-duodenal ulcer.